Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE

There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were includ...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2020-07, Vol.19 (1), p.1-106, Article 106
Main Authors: Liang, Bo, Gu, Ning
Format: Article
Language:English
Subjects:
Brain natriuretic peptide
Clinical trials
Congestive heart failure
Diabetes
Ejection fraction
FIGHT
Glucagon
Glucagon-like peptide 1
Glucose
Heart failure
Heart rate
Hemoglobin
Liraglutide
LIVE
Meta-analysis
Mortality
Peptides
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3
cites cdi_FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3
container_end_page 106
container_issue 1
container_start_page 1
container_title Cardiovascular diabetology
container_volume 19
creator Liang, Bo
Gu, Ning
description There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were included, all overlapped data were summarized and described. No significant changes from baseline in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c, heart rate, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test were observed in FIGHT. In LIVE, liraglutide significantly decreased hemoglobin A1c and inceased 6 min walk test and increased heart rate and serious cardiac adverse events, and there were no statistical differences in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, left ventricular end-systolic volume index, and left ventricular end-diastolic volume index. In this study, we found that there is not enough reason to support the use of liraglutide in patients with heart failure, and importantly, the safety of liraglutide in this particular population remains uncertain. Enhanced recognition the risks and benefits of liraglutide would help guide therapeutic decisions in patients with heart failure.
doi_str_mv 10.1186/s12933-020-01088-3
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b9c8970100c44a839518359f1d2db612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b9c8970100c44a839518359f1d2db612</doaj_id><sourcerecordid>2424712602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3</originalsourceid><addsrcrecordid>eNpdkU-LFDEQxRtR3HX1C3gKePHSmkol6cSDIMv-GRnwsnoN6SQ9k6G7sybdgt_ezM4irqcqqh4_XtVrmrdAPwAo-bEA04gtZbSlQJVq8VlzDrwTLVOcPv-nP2telXKgFDol4WVzhkwioKTnzddtzHY3rkv0gcSZLPtAlhzsMoV5IWkg-2DzQgYbxzWHT1VS4m5fBzlN5Hpzc3tH7OzJdvPj6nXzYrBjCW8e60Xz_frq7vK23X672Vx-2bZOcLq0A6JHPUjLBdc984hKc-F17xwK4ZzSVCOADMg9iAAUkIqeAfNCSCV7vGg2J65P9mDuc5xs_m2SjeZhkPLOVMvRjcH0uuK6-hzqOLcKtQCFQg_gme8lsMr6fGLdr_0UvKtHZzs-gT7dzHFvdumX6bDCKK-A94-AnH6uoSxmisWFcbRzSGsxjDOox3RcVem7_6SHtOa5vuqo4h0wSY-O2Enlciolh-GvGaDmGLs5xW5q7OYhdoP4B3aNmtc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424712602</pqid></control><display><type>article</type><title>Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE</title><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><creator>Liang, Bo ; Gu, Ning</creator><creatorcontrib>Liang, Bo ; Gu, Ning</creatorcontrib><description>There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were included, all overlapped data were summarized and described. No significant changes from baseline in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c, heart rate, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test were observed in FIGHT. In LIVE, liraglutide significantly decreased hemoglobin A1c and inceased 6 min walk test and increased heart rate and serious cardiac adverse events, and there were no statistical differences in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, left ventricular end-systolic volume index, and left ventricular end-diastolic volume index. In this study, we found that there is not enough reason to support the use of liraglutide in patients with heart failure, and importantly, the safety of liraglutide in this particular population remains uncertain. Enhanced recognition the risks and benefits of liraglutide would help guide therapeutic decisions in patients with heart failure.</description><identifier>ISSN: 1475-2840</identifier><identifier>EISSN: 1475-2840</identifier><identifier>DOI: 10.1186/s12933-020-01088-3</identifier><identifier>PMID: 32631360</identifier><language>eng</language><publisher>London: BioMed Central</publisher><subject>Brain natriuretic peptide ; Clinical trials ; Congestive heart failure ; Diabetes ; Ejection fraction ; FIGHT ; Glucagon ; Glucagon-like peptide 1 ; Glucose ; Heart failure ; Heart rate ; Hemoglobin ; Liraglutide ; LIVE ; Meta-analysis ; Mortality ; Peptides ; Ventricle</subject><ispartof>Cardiovascular diabetology, 2020-07, Vol.19 (1), p.1-106, Article 106</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3</citedby><cites>FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3</cites><orcidid>0000-0003-0704-6768 ; 0000-0002-1749-6976</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339504/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2424712602?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Liang, Bo</creatorcontrib><creatorcontrib>Gu, Ning</creatorcontrib><title>Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE</title><title>Cardiovascular diabetology</title><description>There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were included, all overlapped data were summarized and described. No significant changes from baseline in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c, heart rate, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test were observed in FIGHT. In LIVE, liraglutide significantly decreased hemoglobin A1c and inceased 6 min walk test and increased heart rate and serious cardiac adverse events, and there were no statistical differences in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, left ventricular end-systolic volume index, and left ventricular end-diastolic volume index. In this study, we found that there is not enough reason to support the use of liraglutide in patients with heart failure, and importantly, the safety of liraglutide in this particular population remains uncertain. Enhanced recognition the risks and benefits of liraglutide would help guide therapeutic decisions in patients with heart failure.</description><subject>Brain natriuretic peptide</subject><subject>Clinical trials</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>Ejection fraction</subject><subject>FIGHT</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucose</subject><subject>Heart failure</subject><subject>Heart rate</subject><subject>Hemoglobin</subject><subject>Liraglutide</subject><subject>LIVE</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Peptides</subject><subject>Ventricle</subject><issn>1475-2840</issn><issn>1475-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU-LFDEQxRtR3HX1C3gKePHSmkol6cSDIMv-GRnwsnoN6SQ9k6G7sybdgt_ezM4irqcqqh4_XtVrmrdAPwAo-bEA04gtZbSlQJVq8VlzDrwTLVOcPv-nP2telXKgFDol4WVzhkwioKTnzddtzHY3rkv0gcSZLPtAlhzsMoV5IWkg-2DzQgYbxzWHT1VS4m5fBzlN5Hpzc3tH7OzJdvPj6nXzYrBjCW8e60Xz_frq7vK23X672Vx-2bZOcLq0A6JHPUjLBdc984hKc-F17xwK4ZzSVCOADMg9iAAUkIqeAfNCSCV7vGg2J65P9mDuc5xs_m2SjeZhkPLOVMvRjcH0uuK6-hzqOLcKtQCFQg_gme8lsMr6fGLdr_0UvKtHZzs-gT7dzHFvdumX6bDCKK-A94-AnH6uoSxmisWFcbRzSGsxjDOox3RcVem7_6SHtOa5vuqo4h0wSY-O2Enlciolh-GvGaDmGLs5xW5q7OYhdoP4B3aNmtc</recordid><startdate>20200706</startdate><enddate>20200706</enddate><creator>Liang, Bo</creator><creator>Gu, Ning</creator><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0704-6768</orcidid><orcidid>https://orcid.org/0000-0002-1749-6976</orcidid></search><sort><creationdate>20200706</creationdate><title>Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE</title><author>Liang, Bo ; Gu, Ning</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brain natriuretic peptide</topic><topic>Clinical trials</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>Ejection fraction</topic><topic>FIGHT</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucose</topic><topic>Heart failure</topic><topic>Heart rate</topic><topic>Hemoglobin</topic><topic>Liraglutide</topic><topic>LIVE</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Peptides</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Bo</creatorcontrib><creatorcontrib>Gu, Ning</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cardiovascular diabetology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Bo</au><au>Gu, Ning</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE</atitle><jtitle>Cardiovascular diabetology</jtitle><date>2020-07-06</date><risdate>2020</risdate><volume>19</volume><issue>1</issue><spage>1</spage><epage>106</epage><pages>1-106</pages><artnum>106</artnum><issn>1475-2840</issn><eissn>1475-2840</eissn><abstract>There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were included, all overlapped data were summarized and described. No significant changes from baseline in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c, heart rate, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test were observed in FIGHT. In LIVE, liraglutide significantly decreased hemoglobin A1c and inceased 6 min walk test and increased heart rate and serious cardiac adverse events, and there were no statistical differences in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, left ventricular end-systolic volume index, and left ventricular end-diastolic volume index. In this study, we found that there is not enough reason to support the use of liraglutide in patients with heart failure, and importantly, the safety of liraglutide in this particular population remains uncertain. Enhanced recognition the risks and benefits of liraglutide would help guide therapeutic decisions in patients with heart failure.</abstract><cop>London</cop><pub>BioMed Central</pub><pmid>32631360</pmid><doi>10.1186/s12933-020-01088-3</doi><orcidid>https://orcid.org/0000-0003-0704-6768</orcidid><orcidid>https://orcid.org/0000-0002-1749-6976</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-2840
ispartof Cardiovascular diabetology, 2020-07, Vol.19 (1), p.1-106, Article 106
issn 1475-2840
1475-2840
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b9c8970100c44a839518359f1d2db612
source PMC (PubMed Central); Publicly Available Content (ProQuest)
subjects Brain natriuretic peptide
Clinical trials
Congestive heart failure
Diabetes
Ejection fraction
FIGHT
Glucagon
Glucagon-like peptide 1
Glucose
Heart failure
Heart rate
Hemoglobin
Liraglutide
LIVE
Meta-analysis
Mortality
Peptides
Ventricle
title Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A12%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20in%20the%20treatment%20of%20heart%20failure:%20insight%20from%20FIGHT%20and%20LIVE&rft.jtitle=Cardiovascular%20diabetology&rft.au=Liang,%20Bo&rft.date=2020-07-06&rft.volume=19&rft.issue=1&rft.spage=1&rft.epage=106&rft.pages=1-106&rft.artnum=106&rft.issn=1475-2840&rft.eissn=1475-2840&rft_id=info:doi/10.1186/s12933-020-01088-3&rft_dat=%3Cproquest_doaj_%3E2424712602%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-f33d39f6a4549b2d338945d9bcc355cc89093116e34d15e101305b212d55686b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2424712602&rft_id=info:pmid/32631360&rfr_iscdi=true